Long-term adverse event: inflammatory orbitopathy induced by pembrolizumab in a patient with metastatic melanoma
{{output}}
The recent advent of immune checkpoint inhibitors (ICI), including anti-programmed cell death 1 protein (anti-PD-1) agents has revolutionized the therapeutic approach of metastatic malignancies. Yet, ICI can disrupt immune tolerance resulting in enhanced immun... ...
